Core Viewpoint - The new drug pricing proposal by President Trump could lead to a loss of up to $1 trillion for pharmaceutical companies over the next decade, as it links drug prices in the Medicaid program to prices paid in foreign countries [1] Group 1: Industry Response - The pharmaceutical industry is no longer in a wait-and-see mode and is preparing for active lobbying efforts in response to the proposal [1] - Executives from the pharmaceutical sector are scheduled to visit Capitol Hill for discussions, indicating a heightened level of engagement [1] - The lobbying group PhRMA held an emergency conference call with board members to strategize against the proposal [1] Group 2: Legislative Context - The proposal requires House Republicans to link drug prices in the Medicaid program to foreign prices, which could result in significant revenue losses for drug manufacturers [1] - Some Republican lawmakers, including Brett Guthrie, have previously expressed opposition to the "international reference pricing" policy [2] - Guthrie is expected to meet with other Republicans to finalize decisions on Medicaid reform and related proposals [2] Group 3: Political Implications - Trump's previous actions and statements regarding drug pricing and manufacturing suggest a consistent approach towards lowering drug prices and reshoring production [2] - Joe Grogan, former chairman of the White House Domestic Policy Council, noted that Trump's commitment to these issues should not be surprising [2]

据两位接近决策层的知情人士透露，美国制药行业近日收到白宫警告：特朗普政府正在酝酿重启"国际 参考定价"计划，拟将美国药品价格与发达国家市场挂钩。这项被视为"医药界最惧怕政策"的举措，可 能通过医疗保险和医疗补助服务中心(CMS)强制执行，其波及范围或将远超此前威胁的药品关税政策。 消息人士分析，相较于尚在酝酿的药品关税方案，直接引入国际药价参照体系将彻底颠覆美国医药市场 定价机制。美国作为全球药价最高国家(平均是发达国家的三倍)，长期依赖"市场孤岛"维持高昂利润， 若与其他国家药价接轨，药企利润空间将面临史诗级压缩。 值得关注的是，这已是特朗普第二次尝试推动该政策。早在2020年总统任期内，白宫就曾推出类似方 案，但最终被联邦法官以"越权干预市场"为由驳回。分析人士指出，选择此时重启该政策，既是为兑现 大选承诺，更是转移中期选举压力的"转移焦点"策略。 对于政策实施路径，消息人士预测将通过CMS对医保支付体系进行改革，建立基于国际药价的报销标 准。这意味着即便药企维持高价策略，联邦政府也将大幅降低采购价格，倒逼药价体系重构。目前医药 游说集团正紧急动员，试图在最终方案出台前争取豁免条款。 该政策若落地，将彻底 ...